within Pharmacolibrary.Drugs.ATC.A;

model A07AA05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.75e-05,
    adminDuration  = 600,
    adminMass      = 1.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0343,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.012,
    k12             = 1.2,
    k21             = 1.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07AA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Polymyxin B is a cationic polypeptide antibiotic that acts primarily against Gram-negative bacteria by disrupting their outer membrane. It is mainly used to treat infections caused by multidrug-resistant Gram-negative organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Polymyxin B is approved and used today, primarily for severe hospital-acquired infections in settings of antimicrobial resistance.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult critically ill patients receiving intravenous polymyxin B therapy.</p><h4>References</h4><ol><li><p>Tran, TB, et al., &amp; Li, J (2016). Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. <i>International journal of antimicrobial agents</i> 48(6) 592–597. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2016.09.010&quot;>10.1016/j.ijantimicag.2016.09.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27793510/&quot;>https://pubmed.ncbi.nlm.nih.gov/27793510</a></p></li><li><p>Kubin, CJ, et al., &amp; Yin, MT (2018). Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial agents and chemotherapy</i> 62(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01493-17&quot;>10.1128/AAC.01493-17</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29311066/&quot;>https://pubmed.ncbi.nlm.nih.gov/29311066</a></p></li><li><p>Yu, Z, et al., &amp; Yu, Y (2025). Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study. <i>Antimicrobial agents and chemotherapy</i> 69(4) e0185924–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01859-24&quot;>10.1128/aac.01859-24</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40047414/&quot;>https://pubmed.ncbi.nlm.nih.gov/40047414</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07AA05;
